Possible Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors for Reducing Effects of Blood Glucose and also Blood Pressure
Open Access
- 28 August 2020
- journal article
- Published by Asploro Open Access Publications in Asploro Journal of Biomedical and Clinical Case Reports
- Vol. 3 (3), 186-190
- https://doi.org/10.36502/2020/asjbccr.6210
Abstract
Sodium-glucose Cotransporter-2 Inhibitors (SGLT2i) has been in focus for the pharmacotherapy of diabetes. SGLT2i contributes to decreasing blood pressure (BP) to some degree. BP changes were analyzed in 4 well-known mega-studies. They are Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose (EMPA-REG OUTCOME) study, Canagliflozin cardioVascular Assessment Study (CANVAS), Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) and Dapagliflozin Effect on CardiovascuLAR Events (DECLARE)-TIMI 58. The ultimate goal of antihypertensive and hypoglycemic agents is not the achievement of target values, but the suppression of cardiovascular events. SGLT-2i show excellent strategy for event suppression and adjunct method for hypertension.Keywords
This publication has 18 references indexed in Scilit:
- Chronic Diabetes Complications: The Need to Move beyond Classical ConceptsTrends in Endocrinology & Metabolism, 2020
- Clinical Influence of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors for Cardiovascular and Renal Points of ViewPublished by Asploro Open Access Publications ,2020
- 1. Improving Care and Promoting Health in Populations: Standards of Medical Care in Diabetes—2020Diabetes Care, 2019
- Improved home BP profile with dapagliflozin is associated with amelioration of albuminuria in Japanese patients with diabetic nephropathy: the Yokohama add-on inhibitory efficacy of dapagliflozin on albuminuria in Japanese patients with type 2 diabetes study (Y-AIDA study)Cardiovascular Diabetology, 2019
- In Vitro Pharmacological Profile of Ipragliflozin, a Sodium Glucose Co-transporter 2 InhibitorBiological & Pharmaceutical Bulletin, 2019
- Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta‐analysisDiabetes, Obesity and Metabolism, 2019
- Effective Nutritional Guidance for Obesity by Low Carbohydrate Diet (LCD)Asploro Journal of Biomedical and Clinical Case Reports, 2019
- The bark giving diabetes therapy some bite: the SGLT inhibitorsDiabetologia, 2018
- Combined SGLT1 and SGLT2 Inhibitors and Their Role in Diabetes CareDiabetes Technology & Therapeutics, 2018
- Clinical Effect of Low Carbohydrate Diet (LCD): Case ReportDiabetes Case Reports, 2017